De Gregorio

Michael F. Price Memorial Grant from the DeGregorio Family Foundation Awarded for Esophageal Cancer Research

Retrieved on: 
Wednesday, February 21, 2024
Stomach cancer, Neoplasm, De Gregorio, Doctor of Philosophy, MD, Immunotherapy, Esophageal cancer, Grant, Cancer, Mitochondrion, Associate, Patient, Protein, Baylor College of Medicine, Research, Mouse, Baylor University, Pharmaceutical industry

The Grant is named in memory of Michael F. Price, the noted value investor and philanthropist, who was an early supporter of the Foundation.

Key Points: 
  • The Grant is named in memory of Michael F. Price, the noted value investor and philanthropist, who was an early supporter of the Foundation.
  • Normally, the tumor cell 'energy center', called the mitochondria, protect the tumor cell from treatment with either chemotherapy or immunotherapy.
  • "The support of the DeGregorio Family Foundation is critical to the success of our research; we very much appreciate it," said Dr. Ripley.
  • The DeGregorio Family Foundation, founded in 2006 after a 10th member of the DeGregorio family died of stomach cancer, has raised more than $8 million to fund innovative research to cure gastric and esophageal cancers.

Advances Made in Grant to Improve Immunotherapy in Gastroesophageal Cancer

Retrieved on: 
Wednesday, February 7, 2024
Antigen, Massachusetts General Hospital, Immunotherapy, Research, GEA, Stomach cancer, Patient, Safety, Bone marrow, Dana–Farber Cancer Institute, DRS, Cancer, Doctor of Philosophy, De Gregorio, GEMINI, Pharmaceutical industry

They are making strides in their objective of improving immunotherapy in gastroesophageal cancer by identifying and characterizing additional target antigens for next-generation cellular therapies.

Key Points: 
  • They are making strides in their objective of improving immunotherapy in gastroesophageal cancer by identifying and characterizing additional target antigens for next-generation cellular therapies.
  • One immunotherapy that has shown very positive results in blood cancers is Chimeric Antigen Receptor (CAR) T cell therapy.
  • "We are indeed proud to play a part in the development of the next-generation cellular therapy for gastroesophageal cancer by Drs.
  • Dana-Farber Cancer Institute provides expert cancer care while advancing the understanding of cancer and related diseases.

Grant Awarded to Develop Gastric Cancer Vaccine to Prevent Relapse After Surgery

Retrieved on: 
Thursday, February 1, 2024
Immune system, Research, Stomach cancer, Patient, Safety, Diagnosis, Bone marrow, Incidence, Disease, Harvard Medical School, B cell, Vaccination, Stomach, Neoplasm, Cancer, De Gregorio, GEMINI, Vaccine

Gastric cancer is the fourth leading cause of cancer mortality worldwide with mean life expectancy after standard therapy of 12 to 15 months.

Key Points: 
  • Gastric cancer is the fourth leading cause of cancer mortality worldwide with mean life expectancy after standard therapy of 12 to 15 months.
  • Avigan and his team hypothesize that a cancer vaccine targeting gastric cancer can help to train the immune system to eradicate tumor cells throughout the body and prevent disease relapse after surgery.
  • In the present study, they will examine whether designing this type of vaccine against gastric cancer will be effective in generating an immune response directed against gastric cancer cells.
  • They will use a novel approach to generating the vaccine to culture cancer cells outside the body as a part of vaccine production.

Grant Awarded to Identify New Druggable Targets in Gastroesophageal Cancer

Retrieved on: 
Tuesday, January 30, 2024
Dana–Farber Cancer Institute, Patient, Stomach cancer, GEMINI, Research, Knowledge, Cancer, Immunotherapy, De Gregorio, Drug development, Doctor of Philosophy, Therapy, Pharmaceutical industry

NEW YORK, Jan. 30, 2024 /PRNewswire/ -- The DeGregorio Family Foundation with support from the Torrey Coast Foundation Gastro Esophageal Investigator Network Initiative ( GEMINI ) has awarded $200,000 to Eric S. Fischer, PhD, of Dana-Farber Cancer Institute to discover new protein degradation targets in gastroesophageal cancer.

Key Points: 
  • NEW YORK, Jan. 30, 2024 /PRNewswire/ -- The DeGregorio Family Foundation with support from the Torrey Coast Foundation Gastro Esophageal Investigator Network Initiative ( GEMINI ) has awarded $200,000 to Eric S. Fischer, PhD, of Dana-Farber Cancer Institute to discover new protein degradation targets in gastroesophageal cancer.
  • This approach allows the expansion of the scope of targeted therapies beyond conventionally druggable targets such as kinases and holds tremendous promise for new therapies.
  • Patients continue to face poor prognoses following gastric and esophageal cancer diagnoses due to their chemo-resistant behavior and ability to metastasize.
  • Dana-Farber Cancer Institute provides expert cancer care while advancing the understanding of cancer and related diseases.

Coldwell Banker Donates Over Half a Million Dollars in Support of St. Jude Children's Research Hospital® for Third Consecutive Year

Retrieved on: 
Thursday, October 19, 2023
Sale, Housing, NYSE, Heart, Hope, De Gregorio, Bank, Partnership, Coldwell Banker, Travel, Coldwell, St. Jude Children's Research Hospital, Hospital, Real estate, Mass

MADISON, N.J., Oct. 19, 2023 /PRNewswire/ -- Coldwell Banker Real Estate LLC, a subsidiary of Anywhere Real Estate Inc. (NYSE: HOUS), proudly announces the continuation of its impactful partnership with St. Jude Children's Research Hospital® into 2024. The CB Supports St. Jude partnership has exceeded expectations once again, donating an impressive $569,712 in 2023 alone. Coldwell Banker network has donated $1.6 million since the partnership was established in 2020.

Key Points: 
  • The CB Supports St. Jude partnership has exceeded expectations once again, donating an impressive $569,712 in 2023 alone.
  • Coldwell Banker network has donated $1.6 million since the partnership was established in 2020.
  • Within the heart of the network, the story of David DiGregorio, an agent with Coldwell Banker Realty in Waltham, Massachusetts, shines brightly.
  • "Being part of Coldwell Banker and contributing to St. Jude has been one of the most deeply rewarding experiences of my career.

Additional Funding Awarded to Howard University Researcher to Enhance Effectiveness of Immunotherapy in Gastric Cancer

Retrieved on: 
Wednesday, August 9, 2023
DNA, Hereditary diffuse gastric cancer, De Gregorio, Research, Multimedia, Immunotherapy, Doctor of Philosophy, Associate, Howard University College of Medicine, Stomach cancer, DNA repair, Esophageal cancer, Cancer, Patient, Stomach, Pharmaceutical industry, XRCC1

Dr. Kidane-Mulat is working to enhance the effectiveness of immunotherapy in gastric cancers, which now has a very low success rate, in the five percent range.

Key Points: 
  • Dr. Kidane-Mulat is working to enhance the effectiveness of immunotherapy in gastric cancers, which now has a very low success rate, in the five percent range.
  • The overarching goal of this study is to harness XRCC1-deficient gastroesophageal cancer cells that will likely enhance the efficacy of immunotherapy response.
  • Dr. Kidane-Mulat is examining how defective XRCC1 and targeting DNA damage response contributes to aberrant innate immune cells inflammatory response.
  • This work lays the foundation for additional in-depth preclinical studies, and for the development of novel therapeutic strategies for stomach cancer.

Michael F. Price Memorial Grant from DeGregorio Family Foundation Awarded to Improve Survival Rates in Esophageal Cancer

Retrieved on: 
Tuesday, March 7, 2023
MD, Mitochondrion, Esophageal cancer, Therapy, Cell death, Patient, Research, De Gregorio, Baylor University, Stomach cancer, Grant, Cancer, Baylor College of Medicine, Apoptosis, Myeloid leukemia, Neoplasm, Live-cell imaging, Knowledge, Doctor of Philosophy, BH3, Associate, Pharmaceutical industry, Vaccine

The Grant is named in memory of Michael F. Price, the noted value investor and philanthropist, who was an early supporter of the Foundation.

Key Points: 
  • The Grant is named in memory of Michael F. Price, the noted value investor and philanthropist, who was an early supporter of the Foundation.
  • The ultimate goal is to rapidly determine the best approach for treating each individual patient with esophageal cancer.
  • The DeGregorio Family Foundation, founded in 2006 after a 10th member of the DeGregorio family died of stomach cancer, has raised almost $8 million to fund innovative research focused on curing gastroesophageal cancers.
  • "Esophageal adenocarcinoma is the most common subtype of esophageal cancer in the U.S., and it is one of the fastest-growing cancers today," concluded Lynn DeGregorio, President and Founder.

Michael F. Price Memorial Grant from DeGregorio Family Foundation Awarded to Disrupt Cancer Stem Cells with Novel Experimental Drugs

Retrieved on: 
Friday, February 17, 2023
Esophageal cancer, Stomach cancer, De Gregorio, Grant, Patient, CSC, Maintenance, Cell, Metastasis, University, Research, Death, The, WNT, CSCS, Cancer, Doctor of Philosophy, Pharmaceutical industry, Vaccine

The Grant is named in memory of Michael F. Price, the noted value investor and philanthropist, who was an early supporter of the Foundation.

Key Points: 
  • The Grant is named in memory of Michael F. Price, the noted value investor and philanthropist, who was an early supporter of the Foundation.
  • Dr. Capobianco's research is dedicated to targeting cancer stem cell populations by dual inhibition of the Notch and Wnt pathways in upper GI cancers with novel experimental drugs.
  • It is widely accepted that these properties of cancer are driven by distinct populations of cells termed cancer stem cells (CSCs).
  • "We are honored to support this research into ways to destroy the cancer stem cell population in upper GI with novel experimental drugs," concluded Lynn DeGregorio, President and Founder.

Grant Awarded to Enhance the Efficacy of Chemoradiation for Locally Advanced Esophageal Adenocarcinoma

Retrieved on: 
Thursday, November 17, 2022
Quality of life, Doctor of Philosophy, Superoxide dismutase, Cancer, Esophagus, MD, Patient, Radiation, Chandrasekharan, University of Iowa, Esophageal cancer, De Gregorio, GEMINI, University, Research, Multimedia, Clinical trial, Stomach cancer, Neoplasm, Caster, Pharmaceutical industry, Medical imaging, DRS

Esophageal cancer, particularly esophageal adenocarcinoma, has been growing exponentially over the last five decades, especially in the United States.

Key Points: 
  • Esophageal cancer, particularly esophageal adenocarcinoma, has been growing exponentially over the last five decades, especially in the United States.
  • Depending on results, this grant funding could increase up to $1 million.
  • While chemo and radiation improve cure rates, they cause long-term side effects and half of all patients still die of their cancer.
  • The goal of this research is to try to improve the treatment of esophageal adenocarcinoma using drugs which increase cure rates while also decreasing the side effects of chemo and radiation.

Grant Awarded to Develop Genetically Engineered Stem Cell Products to Fight Gastroesophageal Cancer

Retrieved on: 
Wednesday, November 9, 2022
B cell, Monocyte, Foundation, Macrophage, FDA, Travel, Lymphatic system, University, MD, Patient, Courage, Infection, Cancer, Immunotherapy, De Gregorio, CAR, Bone marrow, TME, GEMINI, Inflammation, Doctor of Philosophy, Stomach cancer, Genetic engineering, Cell, Chimeric antigen receptor T cell, Multimedia, Vaccine, Pharmaceutical industry

"We reasoned that genetically engineered macrophages may be better suited to treat solid tumors since these cells are the major immune componentinthetumormicroenvironment(TME)."

Key Points: 
  • "We reasoned that genetically engineered macrophages may be better suited to treat solid tumors since these cells are the major immune componentinthetumormicroenvironment(TME)."
  • Macrophages are normally produced from the bone marrow as monocytes, which travel around the bloodstream and lodge at sites of infection, inflammation and cancer.
  • "This grant will allow me to develop a high-risk yet potentially high-reward cancer treatment paradigm," said Dr. Gill.
  • "We are proud to support the development of a new therapeutic platform for gastroesophageal cancer by Dr. Gill," concluded Lynn DeGregorio, President and Founder.